ADC · 흑색종

4개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleCelldex TherapeuticsPhase 2

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

Melanoma · PD-1

#PD-1#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 60Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin (glembatumumab vedotin)

Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#AdvancedMalignantSolidNeoplasm+2
Trials 9Status Active
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and CDX-301 (glembatumumab vedotin and CDX-301)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and varlilumab (glembatumumab vedotin and varlilumab)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued